
GLOW
Estética
En existencia
50 mg · Disponible
$1,840 MXN
En existencia
50 mg · Disponible
$520
VAT included
Certificate of analysis per batch
≥ 99 % purity (HPLC)
Shipping across Mexico
Delivery in 1–4 business days
Size: 50 mg
Quantity:
Fast & secure payment
Entrega en 1–4 días hábiles
Free shipping across Mexico
On orders from $2,000 MXN — flat $200 MXN below that.
Solo $2,000 for free shipping.






Compare the presentations of GHK-Cu, check their prices in Mexican pesos and review availability for each format. Consult the documentation of the corresponding batch. For scientific research.
GHK-Cu — reagent for research use (RUO). HPLC purity 99.4% with COA per batch.
Sizes and prices: 50 mg $520 MXN ($10 MXN per mg) · 100 mg $780 MXN ($7.8 MXN per mg).
Buy GHK-Cu in Mexico: order online with nationwide shipping in 1-4 business days depending on zone and tracking number. Prices in Mexican pesos. Material for research use only.
GHK-Cu is known internationally as Copper Tripeptide-1 (English INN name). Buy Copper Tripeptide-1 in Mexico / comprar Copper Tripeptide-1 en México: reagent for research use (RUO) with HPLC purity, COA and nationwide shipping.
GHK-Cu is also searched as: Tripeptide de cobre-1, Prezatide copper acetate.
GHK-Cu (Glycyl-L-Histidyl-L-Lysine copper(II) ion) is a copper-tripeptide complex with molecular mass 340.85 Da, formed by the GHK sequence (Gly-His-Lys) covalently bound to a divalent copper ion Cu²⁺ with high affinity (dissociation constant Kd ~10⁻¹⁶ M). It was discovered in 1973 by Dr. Loren Pickart como una fracción del plasma humano capaz de devolver al tejido hepático envejecido características de tejido joven.
GHK is a natural fragment of type I collagen, released during tissue remodeling. Its plasma concentration falls with age (from ~200 ng/mL at age 20 to ~80 ng/mL at 60), a correlation that positions it as key biomolecule in wound healing and skin regeneration.
Structure and properties:
Unlike newer regenerative peptides (BPC-157, TB-500), GHK-Cu acts simultaneously as a modulator of gene expression and as a vehicle for bioavailable copper, a dual function that defines its unique profile. It is used in dermatological research, experimental cosmetics, wound healing, hair regeneration, and cellular senescence. It has no approval as a systemic medication, although topical cosmetic formulations are marketed internationally.
El mecanismo de GHK-Cu es pleiotropic, with two main arms:
1. Broad-spectrum gene expression modulator: estudios transcriptómicos (Pickart et al., Biomed Res Int 2015) muestran que GHK-Cu modula la expresión de more than 4,000 human genes (15% del genoma codificante), reseteando perfiles hacia patrones de tejido joven:
2. Bioavailable and catalytic copper carrier: copper is a cofactor of >12 critical human enzymes (lysyl oxidase for collagen cross-linking, cytochrome c oxidase, Cu/Zn superoxide dismutase, tyrosinase, dopamine-β-hydroxylase). GHK-Cu delivers it in a controlled manner, without the toxicity of free copper.
Documented secondary mechanisms:
Diferencia con otros regenerativos: GHK-Cu acts at the transcriptional level, resetting the aging profile; BPC-157 and TB-500 act on signaling cascades (VEGF/NO and actin). Non-redundant mechanisms.
Formal pharmacokinetic data in humans are limited; most derive from animal and in vitro models.
Topical route (the most studied):
Subcutaneous/intramuscular route:
Oral route: viable parcialmente (absorción vía transportadores PepT1), pero degradación GI significativa; biodisponibilidad sistémica baja (<10%).
Metabolism: degradación proteolítica en glicina, histidina y lisina; el cobre liberado entra al pool corporal.
Elimination/distribución: copper has a prolonged tissue half-life (weeks) in liver, brain and muscle; the tripeptide is cleared rapidly. Broad cutaneous penetration and into hair follicles; modest blood-brain barrier crossing. Degradation by serum peptidases within 1–2 h.
Concentraciones endógenas: ~200 ng/mL en jóvenes, ~80 ng/mL en >60 años, base de la hipótesis de suplementación anti-senescencia.
La evidencia se concentra en preclinical models (rat, mouse, rabbit) and dermatological clinical studies con formulaciones tópicas.\n\nSkin healing:\n- Pollard et al. (Arch Facial Plast Surg 2005; PMID 15655171): aumento de la proliferación y de la expresión de factores de crecimiento en fibroblastos normales e irradiados, en cultivo celular.\n- Maquart et al. (FEBS Lett 1988, J Clin Invest 1993): estimulación de síntesis de matriz extracelular en fibroblastos humanos.\n- Úlceras venosas (Mulder et al.): reducción del 64% en área vs control a 12 semanas.\n\nAesthetic dermatology:\n- Leyden et al. (J Cosmet Dermatol 2002): mejora de arrugas, elasticidad e hidratación en mujeres ≥50 años a 12 semanas con crema GHK-Cu 0.1%.\n- Comparado con vitamina C, retinol y α-hidroxiácidos: equivalente o superior en biomarcadores de remodelación dérmica.\n\nHair regeneration: estudios de Procyte Corporation (estimulación folicular en modelos murinos); uso post-trasplante capilar.\n\nTranscriptómica: Pickart et al. (Biomed Res Int 2015): modulación de 4,000+ genes; Hong et al. (Mol Med Rep 2015): represión de genes asociados a cáncer colorrectal.\n\nOtros: neuroprotección (Alzheimer, regeneración axonal), cardiovascular (reducción de necrosis en infarto), pulmonar (EPOC/fibrosis, Campbell et al. 2012).\n\nLimitations: no existen ensayos clínicos sistémicos formales (fase II/III) parenterales; la evidencia humana es mayormente tópica.
Cosmetic and reparative dermatology (main use in humans):
Hair regeneration:
Systemic regenerative research:
Experimental neuroprotection:
Inflammatory modulation: EPOC, fibrosis pulmonar, enfermedad inflamatoria intestinal (limitado).
Vías por aplicación:
All systemic application is research; topical cosmetic use is approved and available in multiple jurisdictions.
Lyophilized GHK-Cu is reconstituted with bacteriostatic water (BAC) for injection, or with cosmetic vehicles for topical use.
Procedimiento (inyectable):
Reference concentrations:
50 mg vial:
100 mg vial:
Uso tópico (formulación experimental): base hidrofílica (gel de ácido hialurónico, crema neutra), concentración final 0.1%–0.5%, pH óptimo 5.5–7.0. Excluir ácido ascórbico, α-hidroxiácidos y peróxidos (compiten por cobre).
Calculation: volume (mL) = dose (mg) / concentration (mg/mL).
Sealed lyophilized vial:
Vial reconstituted with BAC:
Topical formulation: stability 6–12 months in an opaque container with preservatives; airless containers preferable.
Estabilidad química: estable en pH 4–7; degradación rápida en pH alcalino (>8). Incompatible con quelantes fuertes (EDTA) y antioxidantes que reduzcan Cu²⁺ a Cu⁺ (ácido ascórbico). Estable térmicamente hasta 40 °C transitorio.
Degradación: descartar ante cambio de color, turbidez o precipitado; pH fuera de 5–7 reduce actividad.
Transport: cold gel pack; the lyophilized product tolerates 48–72 h at controlled temperature.
GHK-Cu presents a favorable safety profile, especialmente en uso tópico, ampliamente documentado en cosmética internacional.
Topical use (more established profile):
Systemic use (research):
Genotoxicity: estudios in vitro negativos; al contrario, reprime oncogenes en transcriptómica, sugiriendo perfil protector.
Carcinogenicity: sin estudios a 2 años, pero el perfil anti-tumoral (represión de >70% de oncogenes) y la ausencia de reportes de inducción tumoral sugieren bajo riesgo.
Copper accumulation: riesgo teórico en uso sistémico prolongado a dosis altas. Contraindicated in Wilson's disease. Monitorear cobre sérico y ceruloplasmina en protocolos largos.
Hypersensitivity: precaución con alergia al níquel (reactividad cruzada teórica); reacciones locales en mesoterapia ocasionales y leves.
Pregnancy and lactation: insufficient data, use not advised as a precaution.
Interactions: incompatible con quelantes de cobre (D-penicilamina, trientina); el zinc alto puede interferir con la absorción de cobre.
WADA status: It is NOT on the prohibited list; permitido en deportistas.
Sitio de inyección: dolor leve, eritema transitorio, ocasional coloración azul-verde local que desaparece en 24–48 h.
vs BPC-157: GHK-Cu modulates gene expression + delivers copper; BPC-157 modulates VEGFR2/NO/wound healing. GHK-Cu dominates in skin/hair/anti-aging and is effective topically; BPC-157 in musculoskeletal/GI and requires injection (or oral GI). They are combined in complex cutaneous wound healing.
vs TB-500: TB-500 acts on G-actin and cell migration, more systemic; GHK-Cu on transcription and matrix, predominantly local/dermatological. Combination documented in tissue regeneration.
vs Matrixyl (palmitoyl pentapeptide-4): Matrixyl stimulates collagen via TGF-β-like signaling; GHK-Cu is broader (anti-inflammatory + antioxidant + matrix). Frequently combined.
vs Retinoides: potentes pero irritantes; GHK-Cu menos irritante, perfiles complementarios.
vs Vitamina C: ambos antioxidantes y pro-colágeno por mecanismos distintos, pero incompatibles: el ácido ascórbico reduce Cu²⁺ a Cu⁺ disociando el complejo. No coformular; alternar aplicaciones.
vs Growth factors (EGF, bFGF): recombinants are more expensive and labile; GHK-Cu is more stable, economical, and broader-spectrum.
vs copper-peptide analogs (AHK-Cu, FOXO4-Cu): AHK-Cu has a similar spectrum with less evidence; GHK-Cu is the most studied of the group.
Ventaja: doble mecanismo, evidencia dermatológica robusta, seguridad establecida, costo accesible, no prohibido por WADA. Disadvantage: lower individual potency in systemic musculoskeletal regeneration vs BPC-157/TB-500.
GHK-Cu was discovered in 1973 by Dr. Loren Pickart en la Universidad de California San Francisco, al investigar la diferencia entre plasma de donantes jóvenes y mayores: una fracción peptídica del plasma joven restauraba la síntesis proteica en hepatocitos de rata vieja. La fracción activa era el tripéptido GHK unido a cobre.\n\nHitos:\n- 1973: descubrimiento de la actividad biológica de GHK (Pickart).\n- 1980s: caracterización de la unión al cobre y mecanismos básicos.\n- 1988–1993: Maquart et al. (Francia) demuestran estimulación de matriz extracelular en fibroblastos humanos.\n- 1990s: Procyte Corporation comercializa formulaciones cosméticas y de cicatrización (Tricomin®, Iamin®).\n- 2002: Leyden et al. publican estudios clínicos cosméticos.\n- 2005: Pollard et al. publican efectos sobre proliferación y factores de crecimiento en fibroblastos en cultivo.\n- 2015: Pickart et al. publican el análisis transcriptómico (4,000+ genes; Biomed Res Int).\n- 2018–presente: expansión a neuroprotección, aplicaciones pulmonares y regenerativas.\n\nRegulatorio: approved as a cosmetic ingredient in the USA (FDA OTC monograph), EU (CosIng), Japan, Korea, Australia, and Mexico (COFEPRIS). NOT approved as a systemic parenteral medication. Widely available research reagent. WADA: no prohibido.\n\nPatents: Pickart and Procyte filed multiple patents (1980s–1990s) on formulations; the basic molecule is in the public domain. Academia: >150 indexed publications, with active groups in the USA, France, Korea, and China. for research use.
The characteristic blue color arises from ligand-to-metal charge transfer (LMCT) between the copper ion Cu²⁺ and the imidazole ring of the tripeptide's histidine. It is a visual indicator of an intact complex: if the solution turns green, colorless, or cloudy, this indicates dissociation of the copper and loss of activity. A properly reconstituted solution should retain a transparent blue color.
GHK is the copper-free tripeptide, with lower biological activity (~10-100x lower depending on the assay). GHK-Cu (copper complex) is the main pharmacologically active form. Binding to copper enables its function as an enzymatic cofactor and broad transcriptional modulator. The active commercial products are GHK-Cu, not isolated GHK.
NOT in the same formulation or simultaneous application: ascorbic acid reduces Cu²⁺ to Cu⁺, dissociating the complex and inactivating it. If both are used, alternate morning/night or separate by at least 30 minutes between applications. The same applies to α-hydroxy acids (glycolic, mandelic) and other chelators/reducers.
In cosmetic topical application (0.1-0.5%) visible effects on hydration and firmness typically appear within 4-8 weeks of consistent use. Improvements in fine wrinkles and hyperpigmentation require 12 weeks or more. Clinical studies (Leyden 2002) report significant improvements at 12 weeks with application 2 times/day.
On the contrary: transcriptomic studies show that GHK-Cu represses the expression of >70% of the oncogenes evaluated and activates tumor suppressor and DNA repair genes. There are no preclinical reports of tumor induction. Its molecular profile is rather protective against carcinogenesis, although no formal 2-year studies have been carried out.
GHK-Cu decreases in plasma with age (from ~200 ng/mL at age 20 to ~80 ng/mL at 60). Its supplementation restores transcriptional profiles of young tissue, stimulates extracellular matrix, modulates antioxidants and reduces chronic low-grade inflammation (inflammaging). In vitro studies extend the lifespan of primary cell cultures.
It stimulates the proliferation of hair bulb cells, prolongs the anagen phase of the hair cycle, improves vascularization of the follicle (via VEGF), and reduces perifollicular inflammation. It is used in early androgenetic alopecia, post-hair-transplant, and in studies of alopecia areata. Frequently combined with minoxidil in cosmetic clinical protocols.
NO. GHK-Cu is not included in the prohibited-substances list of WADA or of other major anti-doping agencies. Its use is permitted in competitive athletes, unlike BPC-157, TB-500, and IGF-1, which are prohibited.
In cosmetic clinical studies the effective concentrations range from 0.05% (500 ppm) to 0.5% (5,000 ppm). Higher concentrations do not proportionally increase efficacy and may increase irritation. The generally accepted optimal range is 0.1-0.3% (1,000-3,000 ppm) applied 1-2 times/day to clean skin.
Average rating: 4.8 out of 5, based on 22 customer ratings.
The powder reconstituted super easily and without residue. The QR code with the analysis gives a lot of confidence.
The GHK-CU arrived very fast. It gives me great peace of mind to buy on this platform.
They take great care of the cold chain; the gel packs were still frozen. Very nice touch.
It arrived the day after confirming my payment. Super efficient.
First time buying here and I was delighted. The GHK-CU arrived super fast and the packaging is very discreet.
I bought 3 vials to take advantage of the discount. Recommended.
It is my second order and it arrived super fast to Puebla. One vial came a bit damaged but they replaced it right away without giving me any trouble.
Excellent GHK-CU, it arrived very fast and the presentation is high quality. Very happy with my purchase.
The GHK-CU arrived well. Good product and correct service.
Impeccable cold chain, the gels arrived still rigid.
Excellent thermal packaging; the cold packs arrived at 100%.
Vial with sufficient bubble wrap, nothing broken.
The cold chain was well maintained in its cooler.
Super well protected with thermal packaging.
The GHK-CU arrived in good condition. The courier took an extra day, but the product excellent.
Cooler in excellent condition, gel packs firm.
Consistent quality across batches.
The GHK-CU arrived impeccable. Excellent quality and the shipping was extremely fast.
Meets expectations. Good packaging and fast shipping.
Super good option. They answered me on WhatsApp right away when I had questions and the product has worked really well for me.
Excellent quality for the price. The powder was nicely homogeneous with no lumps, and customer service attended to me extremely quickly.
Analyzed by Janoshik, an independent laboratory. Each report is verifiable per batch at janoshik.com/verify.
Peer-reviewed literature on GHK-Cu, with its PubMed identifier when available:
Full scientific profile: GHK-Cu in the compendium — mechanism of action, studies and technical data sheet.
See the full category catalog: Aesthetics · Recovery.
Lecturas del blog de EXOMA que la editorial asoció a este compuesto: